Works matching IS 2574173X AND DT 2020 AND VI 40 AND IP 2
Results: 14
Issue Information.
- Published in:
- Neuropsychopharmacology Reports, 2020, v. 40, n. 2, p. 113, doi. 10.1002/npr2.12062
- Publication type:
- Article
Increased apolipoprotein E and decreased TNF‐α in the cerebrospinal fluid of nondemented APOE‐ε4 carriers.
- Published in:
- Neuropsychopharmacology Reports, 2020, v. 40, n. 2, p. 201, doi. 10.1002/npr2.12110
- By:
- Publication type:
- Article
Combination of the phosphodiesterase 10A inhibitor, MR1916 with risperidone shows additive antipsychotic‐like effects without affecting cognitive enhancement and cataleptic effects in rats.
- Published in:
- Neuropsychopharmacology Reports, 2020, v. 40, n. 2, p. 190, doi. 10.1002/npr2.12108
- By:
- Publication type:
- Article
Post‐hoc analysis investigating the safety and efficacy of brexpiprazole in Japanese patients with schizophrenia who were switched from other antipsychotics in a long‐term study (Secondary Publication).
- Published in:
- Neuropsychopharmacology Reports, 2020, v. 40, n. 2, p. 122, doi. 10.1002/npr2.12107
- By:
- Publication type:
- Article
Discrepancies in Wechsler Adult Intelligent Scale III profile in adult with and without attention‐deficit hyperactivity disorder.
- Published in:
- Neuropsychopharmacology Reports, 2020, v. 40, n. 2, p. 166, doi. 10.1002/npr2.12106
- By:
- Publication type:
- Article
Pharmacological characterization of a novel potent, selective, and orally active orexin 2 receptor antagonist, SDM‐878.
- Published in:
- Neuropsychopharmacology Reports, 2020, v. 40, n. 2, p. 182, doi. 10.1002/npr2.12105
- By:
- Publication type:
- Article
Apathy symptoms induced by low‐dose venlafaxine: Two cases.
- Published in:
- Neuropsychopharmacology Reports, 2020, v. 40, n. 2, p. 196, doi. 10.1002/npr2.12104
- By:
- Publication type:
- Article
Early improvements of individual symptoms as a predictor of treatment response to asenapine in patients with schizophrenia.
- Published in:
- Neuropsychopharmacology Reports, 2020, v. 40, n. 2, p. 138, doi. 10.1002/npr2.12103
- By:
- Publication type:
- Article
Possible associations between plasma fibroblast growth factor 21 levels and cognition in bipolar disorder.
- Published in:
- Neuropsychopharmacology Reports, 2020, v. 40, n. 2, p. 175, doi. 10.1002/npr2.12102
- By:
- Publication type:
- Article
Time estimation in a case of Tourette's syndrome: Effect of antipsychotic medications.
- Published in:
- Neuropsychopharmacology Reports, 2020, v. 40, n. 2, p. 198, doi. 10.1002/npr2.12101
- By:
- Publication type:
- Article
Serum level of soluble interleukin 6 receptor is a useful biomarker for identification of treatment‐resistant major depressive disorder.
- Published in:
- Neuropsychopharmacology Reports, 2020, v. 40, n. 2, p. 130, doi. 10.1002/npr2.12100
- By:
- Publication type:
- Article
Prefrontal cortex infusion of beta‐hydroxybutyrate, an endogenous NLRP3 inflammasome inhibitor, produces antidepressant‐like effects in a rodent model of depression.
- Published in:
- Neuropsychopharmacology Reports, 2020, v. 40, n. 2, p. 157, doi. 10.1002/npr2.12099
- By:
- Publication type:
- Article
Plasma levels of matrix metalloproteinase‐9 (MMP‐9) are associated with cognitive performance in patients with schizophrenia.
- Published in:
- Neuropsychopharmacology Reports, 2020, v. 40, n. 2, p. 150, doi. 10.1002/npr2.12098
- By:
- Publication type:
- Article
PET technology for drug development in psychiatry.
- Published in:
- Neuropsychopharmacology Reports, 2020, v. 40, n. 2, p. 114, doi. 10.1002/npr2.12084
- By:
- Publication type:
- Article